{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:33:04Z","timestamp":1793572384891,"version":"4.5.0"},"reference-count":45,"publisher":"Cambridge University Press (CUP)","license":[{"start":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T00:00:00Z","timestamp":1584921600000},"content-version":"unspecified","delay-in-days":1543,"URL":"https:\/\/www.cambridge.org\/core\/terms"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["europsy-journal.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Eur. psychiatr."],"published-print":{"date-parts":[[2016]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec id=\"S092493380006781X_abs1\" sec-type=\"other\"><jats:title>Background<\/jats:title><jats:p>The evidence informing the management of cardiovascular risk in patients with psychiatric disorders is weak.<\/jats:p><\/jats:sec><jats:sec id=\"S092493380006781X_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>This cohort study used data from all patients, aged \u2265 30, registered in 140\u00a0primary care practices (<jats:italic>n<\/jats:italic> = 524,952) in London to estimate the risk of developing diabetes, hypertension, hyperlipidemia, tobacco consumption, obesity, and physical inactivity, between 2005 and 2015, for patients with a previous diagnosis of schizophrenia, depression, anxiety, bipolar or personality disorder. The role of antidepressants, antipsychotics and social deprivation in these associations was also investigated. The age at detection of cardiovascular risk factor was compared between patients with and without psychiatric disorders. Variables, for exposures and outcomes, defined from general practitioners records, were analysed using multivariate regression.<\/jats:p><\/jats:sec><jats:sec id=\"S092493380006781X_abs3\" sec-type=\"results\"><jats:title>Results<\/jats:title><jats:p>Patients with psychiatric disorders had an increased risk for cardiovascular risk factors, especially diabetes, with hazard ratios: 2.42 (2.20\u20132.67) to 1.31 (1.25\u20131.37), hyperlipidemia, with hazard ratios: 1.78 (1.60\u20131.97) to 1.25 (1.23\u20131.28), and obesity. Antidepressants, antipsychotics and social deprivation did not change these associations, except for smoking and physical inactivity. Antidepressants were associated with higher risk of diabetes, hypertension and hyperlipidemia. Antipsychotics were associated with a higher risk of diabetes. Antidepressants and antipsychotics were associated with lower risk of other risk factors. Patients with psychiatric conditions have later detection of cardiovascular risk factors. The interpretation of these results should acknowledge the lower rates of detection of risk factors in mentally ill patients.<\/jats:p><\/jats:sec><jats:sec id=\"S092493380006781X_abs4\" sec-type=\"conclusions\"><jats:title>Conclusions<\/jats:title><jats:p>Cardiovascular risk factors require special clinical attention among patients with psychiatric disorders. Further research could study the effect of antidepressants and antipsychotics on cardiovascular risk factors.<\/jats:p><\/jats:sec>","DOI":"10.1016\/j.eurpsy.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,4,8]],"date-time":"2016-04-08T16:03:06Z","timestamp":1460131386000},"page":"8-15","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders"],"prefix":"10.1017","volume":"35","author":[{"given":"M.","family":"P\u00e9rez-Pi\u00f1ar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q.","family":"Foguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Ayis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Robson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Ayerbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"S092493380006781X_bib0038","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291714003110"},{"key":"S092493380006781X_bib0045","first-page":"Cd004162","article-title":"Antipsychotic drug treatment for elderly people with late-onset schizophrenia","volume":"2","author":"Essali","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0044","first-page":"Cd005580","article-title":"Antipsychotic medication for elderly people with schizophrenia","volume":"1","author":"Marriott","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2016.01.034"},{"key":"S092493380006781X_bib0041","first-page":"Cd007954","article-title":"Antidepressants versus placebo for depression in primary care","author":"Arroll","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0023","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.11.003"},{"key":"S092493380006781X_bib0039","doi-asserted-by":"publisher","DOI":"10.2174\/18744737112059990011"},{"key":"S092493380006781X_bib0033","doi-asserted-by":"publisher","DOI":"10.1080\/00048670802653372"},{"key":"S092493380006781X_bib0036","volume-title":"Physical health and severe mental illness","author":"Foguet i Boreu","year":"2012"},{"key":"S092493380006781X_bib0017","first-page":"115","volume-title":"Equity, social determinants and public health programmes","author":"Patel","year":"2010"},{"key":"S092493380006781X_bib0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2014.11.006"},{"key":"S092493380006781X_bib0019","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1093\/eurheartj\/ehs092","article-title":"European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts)","volume":"33","author":"Perk","year":"2012","journal-title":"Eur Heart J"},{"key":"S092493380006781X_bib0005","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2005.02.010"},{"key":"S092493380006781X_bib0020","unstructured":"[20] NICE Pathways. Cardiovascular disease prevention 2016 [Available from: http:\/\/www.pathways.nice.org.uk\/pathways\/cardiovascular-disease-prevention; accessed February 2016]"},{"key":"S092493380006781X_bib0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2014.04.023"},{"key":"S092493380006781X_bib0037","doi-asserted-by":"publisher","DOI":"10.1007\/s10597-013-9614-6"},{"key":"S092493380006781X_bib0015","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.111.639732"},{"key":"S092493380006781X_bib0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.apnu.2013.12.002"},{"key":"S092493380006781X_bib0003","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-8-84"},{"key":"S092493380006781X_bib0025","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2011.04.003"},{"key":"S092493380006781X_bib0002","doi-asserted-by":"publisher","DOI":"10.1016\/S0033-3182(10)70737-4"},{"key":"S092493380006781X_bib0010","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.14r09635"},{"key":"S092493380006781X_bib0026","unstructured":"[26] Quality and Outcomes Framework. NHS The Information Centre [Available on: http:\/\/www.qof.ic.nhs.uk\/; accessed November 2015]."},{"key":"S092493380006781X_bib0012","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2008.08071065"},{"key":"S092493380006781X_bib0014","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2015.2923"},{"key":"S092493380006781X_bib0024","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60879-5"},{"key":"S092493380006781X_bib0018","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001117"},{"key":"S092493380006781X_bib0040","first-page":"Cd004027","article-title":"Antipsychotic medication for childhood-onset schizophrenia","volume":"3","author":"Kennedy","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0007","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20252"},{"key":"S092493380006781X_bib0043","first-page":"Cd003491","article-title":"Antidepressants for depressed elderly","volume":"1","author":"Mottram","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0016","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(03)00402-9"},{"key":"S092493380006781X_bib0013","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.05.024"},{"key":"S092493380006781X_bib0030","volume-title":"Essential psychopharmacology","author":"Stahl","year":"2013"},{"key":"S092493380006781X_bib0031","first-page":"12","article-title":"Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders","volume":"40","author":"Miron","year":"2014","journal-title":"Curr Health Sci J"},{"key":"S092493380006781X_bib0008","doi-asserted-by":"publisher","DOI":"10.1002\/da.22387"},{"key":"S092493380006781X_bib0029","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.2"},{"key":"S092493380006781X_bib0006","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e32835080b7"},{"key":"S092493380006781X_bib0042","first-page":"CD003592","article-title":"Antidepressants for generalised anxiety disorder (GAD)","volume":"2","author":"Kapczinski","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0001","first-page":"A42","article-title":"Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states","volume":"3","author":"Colton","year":"2006","journal-title":"Prev Chronic Dis"},{"key":"S092493380006781X_bib0032","first-page":"Cd000031","article-title":"Antidepressants for smoking cessation","volume":"1","author":"Hughes","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"S092493380006781X_bib0027","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-9-356"},{"key":"S092493380006781X_bib0021","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.303.6801.523-a"},{"key":"S092493380006781X_bib0022","unstructured":"[22] British National Formulary 2015 [Available from: http:\/\/www.medicinescomplete.com\/mc\/bnf\/current\/; accessed December 2015]"},{"key":"S092493380006781X_bib0009","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12439"},{"key":"S092493380006781X_bib0011","doi-asserted-by":"publisher","DOI":"10.1002\/wps.20204"}],"container-title":["European Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092493381602472X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092493381602472X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S092493380006781X","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,23]],"date-time":"2020-03-23T08:28:58Z","timestamp":1584952138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S092493380006781X\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":45,"alternative-id":["S092493380006781X"],"URL":"https:\/\/doi.org\/10.1016\/j.eurpsy.2016.02.004","relation":{},"ISSN":["0924-9338","1778-3585"],"issn-type":[{"value":"0924-9338","type":"print"},{"value":"1778-3585","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular risk factors among patients with schizophrenia, bipolar, depressive, anxiety, and personality disorders","name":"articletitle","label":"Article Title"},{"value":"European Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eurpsy.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}